Comparison of fetal mesencephalic grafts, AAV-delivered GDNF, and both combined in an MPTP-induced nonhuman primate Parkinson's model

Molecular Therapy

Volumn 21, Issue 12, 2013, Pages 2160-2168

  Redmond, D Eugene ^a   Mcentire, Caleb R S ^a   Kingsbery, Joseph P ^a   Leranth, Csaba ^a   Elsworth, John D ^a   Bjugstad, Kimberly B ^b   Roth, Robert H ^a   Samulski, Richard J ^c   Sladek, John R ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOVIRUS VECTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; SODIUM CHLORIDE;

ADENO ASSOCIATED VIRUS; ADULT; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG BRAIN LEVEL; DRUG EFFICACY; FETAL TISSUE TRANSPLANTATION; GRAFT SURVIVAL; HISTOPATHOLOGY; MALE; MESENCEPHALON; NONHUMAN; PARKINSON DISEASE; PUTAMEN; TISSUE IMPLANT; VENTRAL MESENCEPHALON; VIRAL GENE DELIVERY SYSTEM;

ADENO-ASSOCIATED VIRUS; ANIMALIA; PRIMATES;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN TISSUE TRANSPLANTATION; CERCOPITHECUS AETHIOPS; COMBINED MODALITY THERAPY; CORPUS STRIATUM; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINERGIC NEURONS; FETAL TISSUE TRANSPLANTATION; GENETIC THERAPY; GENETIC VECTORS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; INFECTIOUS ANEMIA VIRUS, EQUINE; MALE; MESENCEPHALON; MPTP POISONING; PARKINSON DISEASE;

EID: 84890125492     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.180     Document Type: Article

References (48)

1. Lin, LF, Doherty, DH, Lile, JD, Bektesh, S and Collins, F (1993). GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260: 1130-1132
2. Kearns, CM, Cass, WA, Smoot, K, Kryscio, R and Gash, DM (1997). GDNF protection against 6-OHDA: Time dependence and requirement for protein synthesis. J Neurosci 17: 7111-7118
3. Sullivan, AM, Opacka-Juffry, J and Blunt, SB (1998). Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo. Eur J Neurosci 10: 57-63
4. Sauer, H, Rosenblad, C and Björklund, A (1995). Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci USA 92: 8935-8939
5. Kirik, D, Rosenblad, C and Björklund, A (2000). Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci 12: 3871-3882
6. Ai, Y, Markesbery, W, Zhang, Z, Grondin, R, Elseberry, D, Gerhardt, GA et al. (2003). Intraputamenal infusion of GDNF in aged rhesus monkeys: Distribution and dopaminergic effects. J Comp Neurol 461: 250-261
7. Lysaght, MJ and Aebischer, P (1999). Encapsulated cells as therapy. Sci Am 280: 76-82
8. Sautter, J, Tseng, JL, Braguglia, D, Aebischer, P, Spenger, C, Seiler, RW et al. (1998). Implants of polymer-encapsulated genetically modified cells releasing glial cell line-derived neurotrophic factor improve survival, growth, and function of fetal dopaminergic grafts. Exp Neurol 149: 230-236
9. Mittoux, V, Joseph, JM, Conde, F, Palfi, S, Dautry, C, Poyot, T et al. (2000). Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. Hum Gene Ther 11: 1177-1187
10. Georgievska, B, Kirik, D and Björklund, A (2004). Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dosedependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J Neurosci 24: 6437-6445
11. Georgievska, B, Kirik, D and Björklund, A (2002). Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 177: 461-474
12. Kirik, D, Rosenblad, C, Bjorklund, A and Mandel, RJ (2000). Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 20: 4686-4700
13. Kordower, JH, Emborg, ME, Bloch, J, Ma, SY, Chu, Y, Leventhal, L et al. (2000). Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of parkinson's disease. Science 290: 767-773
14. Eslamboli, A, Baker, HF, Ridley, RM and Annett, LE (2003). Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of parkinson's disease in marmoset monkeys. Exp Neurol 183: 418-429
15. Elsworth, JD, Redmond, DE Jr, Leranth, C, Bjugstad, KB, Sladek, JR Jr, Collier, TJ et al. (2008). AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons. Exp Neurol 211: 252-258
16. Eberling, JL, Kells, AP, Pivirotto, P, Beyer, J, Bringas, J, Federoff, HJ et al. (2009). Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys. Hum Gene Ther 20: 511-518
17. Johnston, LC, Eberling, J, Pivirotto, P, Hadaczek, P, Federoff, HJ, Forsayeth, J et al. (2009). Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther 20: 497-510
18. Rosenblad, C, Georgievska, B and Kirik, D (2003). Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. Eur J Neurosci 17: 260-270
19. Batchelor, PE, Wills, TE, Hewa, AP, Porritt, MJ and Howells, DW (2008). Stimulation of axonal sprouting by trophic factors immobilized within the wound core. Brain Res 1209: 49-56
20. Georgievska, B, Kirik, D, Rosenblad, C, Lundberg, C and Björklund, A (2002). Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 13: 75-82
21. Kordower, JH, Freeman, TB, Snow, BJ, Vingerhoets, FJ, Mufson, EJ, Sanberg, PR et al. (1995). Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 332: 1118-1124
22. Mendez, I, Sanchez-Pernaute, R, Cooper, O, Viñuela, A, Ferrari, D, Björklund, L et al. (2005). Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 128(Pt 7): 1498-1510
23. Rosenstein, JM (1995). Why do neural transplants survive? An examination of some metabolic and pathophysiological considerations in neural transplantation. Exp Neurol 133: 1-6
24. Redmond, DE Jr (2002). Cellular replacement therapy for parkinson's disease-where we are today? Neuroscientist 8: 457-488
25. Ma, Y, Feigin, A, Dhawan, V, Fukuda, M, Shi, Q, Greene, P et al. (2002). Dyskinesia after fetal cell transplantation for parkinsonism: A PET study. Ann Neurol 52: 628-634
26. Redmond, DE Jr, Elsworth, JD, Roth, RH, Leranth, C, Collier, TJ, Blanchard, B et al. (2009). Embryonic substantia nigra grafts in the mesencephalon send neurites to the host striatum in non-human primate after overexpression of GDNF. J Comp Neurol 515: 31-40
27. Markakis, EA, Vives, KP, Bober, J, Leichtle, S, Leranth, C, Beecham, J et al. (2010). Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. Mol Ther 18: 588-593
28. Sladek, JR Jr, Bjugstad, KB, Collier, TJ, Bundock, EA, Blanchard, BC, Elsworth, JD et al. (2008). Embryonic substantia nigra grafts show directional outgrowth to cografted striatal grafts and potential for pathway reconstruction in nonhuman primate. Cell Transplant 17: 427-444
29. Su, X, Kells, AP, Huang, EJ, Lee, HS, Hadaczek, P, Beyer, J et al. (2009). Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 20: 1627-1640
30. Li, JY, Englund, E, Holton, JL, Soulet, D, Hagell, P, Lees, AJ et al. (2008). Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14: 501-503
31. Strömberg, I, Björklund, L, Johansson, M, Tomac, A, Collins, F, Olson, L et al. (1993). Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp Neurol 124: 401-412
32. Martin, D, Miller, G, Cullen, T, Fischer, N, Dix, D and Russell, D (1996). Intranigral or intrastriatal injections of GDNF: Effects on monoamine levels and behavior in rats. Eur J Pharmacol 317: 247-256
33. Hudson, J, Granholm, AC, Gerhardt, GA, Henry, MA, Hoffman, A, Biddle, P et al. (1995). Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res Bull 36: 425-432
34. Elsworth, JD, Taylor, JR, Sladek, JR Jr, Collier, TJ, Redmond, DE Jr and Roth, RH (2000). Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in oldworld primates one year after MPTP treatment. Neuroscience 95: 399-408
35. Zigmond, MJ, Abercrombie, ED, Berger, TW, Grace, AA and Stricker, EM (1990). Compensations after lesions of central dopaminergic neurons: Some clinical and basic implications. Trends Neurosci 13: 290-296
36. Lawrence, MS and Redmond, DE Jr (1991). MPTP lesions and dopaminergic drugs alter eye blink rate in African green monkeys. Pharmacol Biochem Behav 38: 869-874
37. Taylor, JR, Elsworth, JD, Roth, RH, Sladek, JR Jr and Redmond, DE Jr (1994). Behavioral effects of MPTP administration in the vervet monkey: A primate model of parkinson's disease. In: Woodruff, ML and Nonneman, AJ (eds). Toxin-Induced Models of Neurological Disorders. Plenum Press: New York. pp. 139-174
38. Taylor, JR, Elsworth, JD, Roth, RH, Sladek, JR Jr, Collier, TJ and Redmond, DE Jr (1991). Grafting of fetal substantia nigra to striatum reverses behavioral deficits induced by MPTP in primates: A comparison with other types of grafts as controls. Exp Brain Res 85: 335-348
39. Redmond, DE Jr (2011). Behavioral assessment in the African green monkey after MPTP administration. In: Lane, E and Dunnett, S (eds). Neuromethods: Animal Models of Movement Disorders. Springer Science: New York
40. Fahn, S and Elton, RL; Members of the UPDRS Development Committee (1987). Unified Parkinson's disease rating scale. In: Fahn, S, Marsden, CD, Calne, DB and Goldstein, M (eds). Recent Developments in Parkinson's Disease, vol. 2. Macmillan Healthcare Information: Florham Park, NJ. pp. 153-164
41. Choi, VW, Asokan, A, Haberman, RA, McCown, TJ and Samulski, RJ (2006). Production of recombinant adeno-associated viral vectors and use for in vitro and in vivo administration. Curr Protoc Neurosci Chapter 4: Unit 4.17
42. Rabinowitz, JE, Rolling, F, Li, C, Conrath, H, Xiao, W, Xiao, X et al. (2002). Crosspackaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76: 791-801
43. Xiao, X, Li, J and Samulski, RJ (1998). Production of high-titer recombinant adenoassociated virus vectors in the absence of helper adenovirus. J Virol 72: 2224-2232
44. Sladek, JR Jr, Elsworth, JD, Taylor, JR, Roth, RH and Redmond, DE, Jr (1995). Techniques for neural transplantation in non-human primates. In: Ricordi, C and Landes, RG (eds). Techniques for Neural Transplantation. CRC Press: Austin, TX. pp 391-408
45. During, MJ, Samulski, RJ, Elsworth, JD, Kaplitt, MG, Leone, P, Xiao, X et al. (1998). In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther 5: 820-827
46. Morrow, BA, Redmond, DE Jr, Roth, RH and Elsworth, JD (2005). Development of A9/ A10 dopamine neurons during the second and third trimesters in the African green monkey. J Comp Neurol 488: 215-223
47. Hsu, SM, Raine, L and Fanger, H (1981). Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29: 577-580
48. Morrow, BA, Roth, RH, Redmond, DE and Elsworth, JD (2011). Impact of methamphetamine on dopamine neurons in primates is dependent on age: Implications for development of parkinson's disease. Neuroscience 189: 277-285 Stroke